NEW YORK--(EON: Enhanced Online News)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aratana Therapeutics, Inc. (NASDAQ:PETX) resulting from allegations that Aratana may have issued materially misleading business information to the investing public.
“it now anticipates that ENTYCE…will be commercially available by late 2017”
On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine (“CVM”) had requested more information about Aratana’s appetite stimulation drug ENTYCE. Aratana stated that “it now anticipates that ENTYCE…will be commercially available by late 2017” and that the CVM’s request was in response to Aratana’s “post-approval supplement request to transfer manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale” On this news, shares of Aratana fell $1.44 per share or over 17% to close at $6.59 per share on February 6, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Aratana investors. If you purchased shares of Aratana on or before February 3, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1049.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.